Thomson Reuters | Conferences

Healthcare

Join Thomson Reuters researchers at key research industry events as they share relevant findings of their most recent healthcare research. Selected posters and presentations from past conferences are available for download.

OCTOBER

NASHP 24th Annual State Health Policy Conference
October 3-5, 2011
Kansas City, MO

2011 Clinical Conference of the American College of Nurse Practitioners
October 5-9
Denver CO

Ellis L, Bailey R, Forlenza J, Senbetta M, Blumberg P.
Patterns of preoperative anemia screening (PAS) in elective total hip replacement (THR) or total knee replacement (TKR) surgery

Ellis L, Bailey R, Forlenza J, Senbetta M, Blumberg P.
Inpatient transfusion practice and perisurgical outcomes in adult elective total hip replacement (THR) or total knee replacement (TKR) surgery patients <65 years of age

The Fifth Annual Meeting of the PMRG Institute
Oct 16-18
Jersey City, NJ

Academy of Managed Care Pharmacy’s 2011 Educational Conference
Oct 19-21
Atlanta, GA

Whiteley J, Landsman-Blumberg PB, Cao Z, Alvir J, Harnett J.
Effects of a Desvenlafaxine Prior Authorization on Healthcare Resource Utilization and Costs in Commercially Insured Patients

Society for Medical Decision Making 2011 Annual Meeting
Oct 23-26
Chicago, IL

International Society for Quality of Life
Oct 26-29
Denver, CO

Gagnon, D.
Knowledge, Belief, and Content Validity of Measures of Treatment Satisfaction

NOVEMBER 2011

ISPOR 14th Annual European Congress
Nov 5-8
Madrid, Spain

POSTER SESSION I
6 November 2011
12:00 - 20:00

Marder WD, Chang S, Pepitone T, Hatzmann M, Mark T, Goodrich K.
US Government Initiatives for Supporting Comparative Effectiveness Research, An Example from Project Libra PMH8

Bonafede M, Locklear JC, Wahlqvist P, Liberty Fajutrao L, Szamosi J, Pan K, Eriksson H.
The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length of Hospitalisation of Patients with Acute Bipolar Mania. PMH72

Bonafede M, Gandra SR, Watson C, Princic N, Fox KM.
Cost of etanercept, adalimumab, and infliximab per treated patient across adult indications using real world data.
PMS14

Palmer LA, Fowler R, Shi N, Dastani H, Abouzaid S3, Kim E.
Impact of Patient Cost-Sharing Arrangements for Disease Modifying Terapies on Treatment Compliance among U.S. Patients with Multiple Sclerosis PND61

WORKSHOPS - SESSION III
7 November 2011
14:00 - 15:00

Bourke A, Herings RMC, Huse D, LoCasale RJ.
Linking Existing Databases – Poisoned Chalice or Holy Grail? W21

POSTER SESSION III
8 November 2011
08:00 - 16:00

Bonthapally V, Ganguli A, Landsman-Blumberg P, McMorrow D, Ray S.
Healthcare Resources and Costs across Lines of Therapies in Insured Patients with Metastatic Breast Cancer in the United States PCN51

Meyer N, Weldon D, Huse DM.
Trends in Chemotherapy and Biologic Treatment of US Colorectal Cancer Patients PCN184

Juneau P, Huse DM.
Model and Covariate Visualization Aids for Enhancing the Interpretation of Steps in the High Dimensional Propensity Scoring Adjustment Procedure PRM54

Gagnon DD.
Estimating the Confidence Interval for the Cost-effectiveness Ratio from a Family of Regressions on Net Monetary Benefit
PRM59

American College of Allergy, Asthma, and Immunology (ACAAI’s) 2011 Annual Meeting
Nov 3-8
Boston, MA

Landsman-Blumberg P, Wei W, Douglas D, Smith D, Camargo C.
A Retrospective Database Study of Characteristics of US Adults Seen in the Emergency Department or Hospital with Food-induced Anaphylaxis

Landsman-Blumberg P, Wei W, Douglas D, Smith D, Camargo C.
A Retrospective Database Study of Concordance with Recommended Post-Discharge Anaphylaxis Care among US Adults Seen in the Emergency Department or Hospital with Food-induced Anaphylaxis

ACR/ARHP Annual Scientific Meeting
Nov 4-9
Chicago, IL

Song X, Kan HJ, Johnson BH, Bechtel B, O’Sullivan D, Molta C.
Healthcare Utilization of Patients with Systemic Lupus Erythematosus in a U.S. Medicaid Population

Johnston S, Turpcu A, Shi N, Moawad D, Alexander K.

Risk of Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Subsequent-line Biologic Disease Modifying Antirheumatic Drugs after Switching from First-line Anti-tumor Necrosis Factor Agents

Bonafede B, Watson C, Fox KM, Wilson KL, Gandra S.
Anti-Tumor Necrosis Factor Dose Escalation Among Biologic Naïve Rheumatoid Arthritis Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation

Bonafede B, Watson C, Fox KM, Princic N, Gandra S.
Tumor Necrosis Factor Blocker Treatment Patterns After Discontinuation within the First Year of Therapy Initiation in Rheumatoid Arthritis Patients in a Real-World Managed Care Setting

American Society of Nephrology (ASN) Kidney Week 2011 Annual Meeting
Nov 10-13
Philadelphia, PA

Lee A. Song X, Belozeroff V, Diakun D, Goodman W.

Costs of Care and Major Clinical Events among Chronic Dialysis Patients with and without Treatment for sHPT: A Descriptive Study of Claims Data

Gitlin M, Wan S, Song X, Carson JL, Spiegel DM, Custer B, Ashfaq A, Varker H, Cappell K.
Outpatient (OP) Red Blood Cell (RBC) Transfusion Payments among Patients on Chronic Dialysis

American Heart Association (AHA) Scientific Sessions 2011
Nov 12-16
Orlando, FL

Allen LA, Smoyer Tomic K, Wilson KL, Smith DM, Agodoa I.
Predictors of 30-Day Readmission Among Commercially Insured and Medicaid-Enrolled Patients Hospitalized with Systolic Heart Failure Poster

The University of Michigan Center for Value-Based Insurance Design (V-BID Center) 2011 Symposium
Nov 16
Ann Arbor, Michigan

2011 American Society of Consultant Pharmacists (ASCP) Annual Meeting and Convention
Nov 16-18
Phoenix, AZ

Shah S, Knoth R, Margolis J, Alvir J, Lenhart G.
The Effect of Alzheimer's Disease Medication Cost-Share Burden on Chronic Disease Medication Adherence and Clinical Outcomes

MARCH 2012

70^th Annual Meeting of the American Academy of Dermatology
Mar 16-20
San Diego, CA

Bonafede M, Fox KM, Watson C, Gandra SR. Cost of tumor necrosis factor (TNF) blocker per treated psoriatic arthritis (PSA) patient using drug utilization data from a US managed care population.

Bonafede M, Watson C, Gandra SR, Fox KM. Using real-world drug utilization to estimate tumor necrosis factor (TNF) blocker cost for treated psoriasis (PsO) patient in a managed care setting.

Bonafede M, Fox KM, Watson C, Gandra SR. Etanercept and adalimumab treatment patterns after discontinuation within the first year of therapy initiation in psoriasis (PSO) patients in a large managed care population.

Bonafede M, Fox KM , Watson C, Gandra SR. Tumor necrosis factor (TNF) blocker treatment patterns after discontinuation within the first year of therapy initiation in psoriatic arthritis (PSA) patients in a real-world managed care setting.

Bonafede M, Fox KM , Gandra SR, Watson C. Dose escalation of TNF-blocker therapy among US managed care patients with psoriasis.